Abstract: A novel crystalline form of Tavapadon (hereinafter referred to as “Compound I”) and its preparation method, pharmaceutical compositions containing this crystalline form, and its use in the preparation of dopamine D1/D5 receptor agonist drugs and in the treatment of Parkinson's disease. The crystalline form of Compound I provided by the present disclosure has one or more improved properties compared to prior arts, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.

Abstract: The present invention relates to a new crystal form of tolebrutinib (hereinafter referred to as “compound I”), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of same in the preparation of a BTK inhibitor drug and a drug for treating multiple sclerosis. The crystal form of tolebrutinib provided has one or more improved properties compared with the prior art, and is of great value to the optimization and development of drugs in the future.

Abstract: Provided are novel crystalline forms of Nirogacestat (Referred to as “Compound I”) dihydrobromide and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing ?-secretase inhibitor drugs and drugs for treating desmoid tumors. Compared with prior arts, the provided crystalline forms of Compound I dihydrobromide have one or more improved properties, which solve the problems of the prior art and are of great value to the optimization and development of the drugs.

Abstract: Disclosed is a crystalline form of Tolebrutinib (hereinafter referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing BTK inhibitor drugs and drugs for treating multiple sclerosis. The provided crystalline form of Tolebrutinib has one or more improved properties and has significant value for future drug optimization and development.

Abstract: The present disclosure relates to a novel crystalline form of Tolebrutinib (hereinafter referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing BTK inhibitor drugs and drugs for treating multiple sclerosis.

Abstract: Disclosed is a crystalline form of Tolebrutinib (hereinafter referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing BTK inhibitor drugs and drugs for treating multiple sclerosis. The provided crystalline form of Tolebrutinib has one or more improved properties and has significant value for future drug optimization and development.

Abstract: A novel crystalline form of Compound I and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing hypoxia inducible factor prolyl hydroxylase inhibitor drugs and drugs for treating conditions mediated by hypoxia inducible factors. Compared with prior arts, the crystalline form of Compound I have one or more improved properties, which is of great value to the optimization and development of the drugs.

Abstract: The present disclosure relates to a novel crystalline form of upadacitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical compositions containing the crystalline form, use of the upadacitinib crystalline form for preparing JAK inhibitor drug, and use of the upadacitinib crystalline form for preparing drugs treating rheumatoid arthritis. The crystalline form of upadacitinib provided by the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development.

Abstract: A system is disclosed for providing backward and forward traceability by a methodology which identifies discrete components (die, substrate and/or passives) that are included in a semiconductor device. The present technology further includes a system for generating a unique identifier and marking a semiconductor device with the unique identifier enabling the semiconductor device, and the discrete components within that device, to be tracked and traced through each process and test in the production of the semiconductor device.